List of Excipients in Branded Drug ZANTAC 360

« Back to Dashboard

Generic Drugs Containing ZANTAC 360

Company	Ingredient	NDC	Excipient
Chattem Inc	famotidine	41167-0360	CARNAUBA WAX
Chattem Inc	famotidine	41167-0360	CELLULOSE, MICROCRYSTALLINE
Chattem Inc	famotidine	41167-0360	FERRIC OXIDE RED

What are the Most Frequently-Used Excipients in ZANTAC 360?

# Of NDCs	Excipient
5	CARNAUBA WAX
5	CELLULOSE, MICROCRYSTALLINE
5	FERRIC OXIDE RED

Zantac 360 Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Zantac 360 is an over-the-counter famotidine product positioned as an alternative to ranitidine-based Zantac. Its commercial opportunity depends less on active-ingredient exclusivity and more on formulation differentiation, consumer trust, manufacturing reliability, retail distribution, and control of excipient-related quality risks. Famotidine is a mature active ingredient with limited composition-of-matter protection. The strongest opportunities are in fast-dissolving dosage forms, chewables, liquid products, combination products, improved packaging, and low-risk reformulations that preserve the established Zantac 360 brand experience.

What is Zantac 360 and which active ingredient does it contain?

Zantac 360 contains famotidine, an H2-receptor antagonist that reduces gastric acid secretion. It is marketed for relief and prevention of heartburn associated with acid indigestion. The product replaced ranitidine-based Zantac products following the withdrawal of ranitidine products over N-nitrosodimethylamine, or NDMA, contamination concerns.[1]

The principal commercial presentations include:

Product characteristic	Zantac 360 positioning
Active ingredient	Famotidine
Therapeutic class	H2-receptor antagonist
Primary use	Heartburn relief and prevention
Retail status	OTC
Common strengths	10 mg and 20 mg
Dosage form	Film-coated tablet
Biosimilar exposure	Not applicable
Core patent status	Famotidine molecule is mature and off-patent
Primary differentiation	Brand, formulation, packaging, trust and distribution

Zantac 360 is not a biologic and does not face biosimilar substitution. Competitive pressure comes from generic famotidine tablets, private-label products, Pepcid-branded products, antacids, alginate products, proton-pump inhibitors and combination heartburn treatments.

What excipients are used in Zantac 360 tablets?

Public product labeling identifies a conventional immediate-release tablet platform. Reported inactive ingredients include microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, magnesium stearate, hypromellose, polyethylene glycol, talc, titanium dioxide and coating-related materials.[2]

The functional role of the principal excipients is as follows:

Excipient class	Typical function	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and manufacturability
Pregelatinized starch	Binder and disintegrant	Helps tablet formation and breakup
Croscarmellose sodium	Superdisintegrant	Supports rapid disintegration
Magnesium stearate	Lubricant	Controls ejection and tooling friction
Hypromellose	Film former	Protects the tablet and improves appearance
Polyethylene glycol	Coating plasticizer	Reduces coating brittleness
Talc	Glidant or anti-tacking agent	Supports powder flow and coating performance
Titanium dioxide	Opacifier and colorant	Provides a uniform film appearance

The formulation is technically conventional. Its value lies in balanced performance rather than a novel excipient system. Famotidine is a low-dose active ingredient, which gives formulators room to optimize tablet size, disintegration, coating, taste masking and manufacturability without materially increasing unit weight.

How strong is the Zantac 360 formulation patent estate?

The commercial patent position is weaker than the brand position. Famotidine was approved decades ago, and the basic active ingredient is not a current source of meaningful exclusivity. A competitor can generally formulate and sell OTC famotidine if it complies with FDA requirements and avoids Zantac trademarks and protected trade dress.

The relevant protection categories are:

Protection category	Likely importance to Zantac 360
Famotidine composition patent	Low; historical protection has expired
Basic immediate-release tablet	Low to moderate
Specific excipient ratio	Potentially relevant only if claimed and enforceable
Coating system	Potentially relevant but easy to design around
Trade dress and trademarks	High for branded competitors
FDA regulatory status	Important for lawful marketing
Manufacturing know-how	Moderate; relevant to quality and cost
Packaging configuration	Moderate; relevant to shelf life and consumer use
Consumer brand equity	High

A formulation patent could protect a particular dissolution profile, coating, taste-masking system, impurity-control strategy or manufacturing process. It would not automatically prevent generic famotidine products from entering the market. The practical barrier would depend on claim scope, validity, infringement evidence and the availability of alternative excipient systems.

No biosimilar litigation analysis applies. The relevant legal risks are generic competition, trademark infringement, formulation patent disputes and regulatory challenges.

What is the Orange Book status of Zantac 360?

Zantac 360 is an OTC famotidine product rather than a biologic. Orange Book relevance depends on the specific approved application and whether the sponsor has listed patents covering the marketed product. The brand name does not create exclusivity, and an OTC product does not receive protection merely because it uses a recognized consumer brand.

The principal regulatory pathways for competing products are:

1. An abbreviated new drug application, or ANDA, referencing an approved famotidine product where the reference-product structure permits that pathway.
2. A separate OTC application or monograph-based pathway, depending on the product, active ingredient, strength, labeling and regulatory conditions.
3. A private-label or store-brand product manufactured by a contract manufacturer.
4. A line extension supported by a supplement or new application.

Paragraph IV challenges would matter only if a competitor relies on an ANDA and certifies that listed patents are invalid, unenforceable or not infringed. Because famotidine is a mature active ingredient, Paragraph IV activity is more likely to concern a specific formulation, dosage form or method-of-use claim than the molecule itself.

When does Zantac 360 lose exclusivity?

Zantac 360 does not have a meaningful remaining period of active-ingredient exclusivity. Its competitive exclusivity is primarily commercial.

Exclusivity type	Zantac 360 position
New chemical entity exclusivity	Not applicable to mature famotidine
Orphan exclusivity	Not applicable
Pediatric exclusivity	No strategic relevance identified
Biologic exclusivity	Not applicable
Core active-ingredient patent	Historical and expired
Brand exclusivity	Trademark-based, not market exclusivity
Formulation exclusivity	Depends on specific patent or regulatory protection
Retail exclusivity	Dependent on contracts and channel access

This structure favors fast-following products. A competitor does not need to reproduce every excipient or manufacturing step. It needs a compliant famotidine product with acceptable stability, dissolution, labeling and supply economics.

Which excipient risks matter most for Zantac 360?

Nitrosamine and nitrite control

The historical Zantac withdrawal changed consumer and regulator expectations for acid-reducing products. Famotidine is not ranitidine, but a famotidine product still requires a controlled impurity strategy. Excipients can introduce nitrite, nitrate, peroxide or other reactive impurities. The risk is influenced by supplier, lot, storage condition, water activity, temperature and packaging.

A robust strategy includes:

• Supplier qualification for nitrite and nitrate variability.
• Risk-based testing of excipient lots.
• Control of peroxide-forming materials.
• Low-moisture processing where justified.
• Stability studies under accelerated and long-term conditions.
• Packaging that limits moisture and oxygen exposure.
• Defined investigation limits for unknown and specified impurities.

The brand opportunity is clear: documented impurity controls can support retailer confidence and consumer messaging, even when the controls are not prominent on the package.

Magnesium stearate and dissolution

Magnesium stearate is useful but can slow wetting and dissolution when over-lubrication occurs. Blend time, lubricant concentration, particle size and surface area should be controlled. A competitor seeking faster onset can optimize lubrication and disintegration without creating a novel dosage form.

Coating performance

Film coating improves swallowability, appearance and mechanical protection. Excessive coating weight can delay disintegration. Coating variability can affect tablet identification, consumer perception and packaging-line performance.

Titanium dioxide and colorant strategy

Titanium dioxide and other colorants may create regulatory and consumer-positioning issues in selected markets. A reformulated product can use a simplified coating system or alternative colorants. The commercial benefit is greatest in markets where consumers seek "clean label" products or where retailer policies restrict certain colorants.

Starch and cellulose supply

Microcrystalline cellulose and pregelatinized starch are widely available, but global supply interruptions can affect cost and continuity. Dual sourcing is practical. An excipient substitution should be supported by comparative dissolution, stability, hardness, friability, content uniformity and bioequivalence data where required.

What formulations are protected or commercially available for famotidine?

The existing Zantac 360 tablet leaves several formulation spaces open:

Formulation opportunity	Consumer benefit	Technical challenge
Chewable tablet	No water required	Famotidine bitterness and mouthfeel
Orally disintegrating tablet	Rapid administration	Taste masking and friability
Effervescent tablet	Rapid dispersion	Moisture sensitivity and packaging
Liquid suspension	Pediatric and geriatric use	Physical and chemical stability
Unit-dose stick pack	Portable dosing	Powder flow and moisture control
Dual-action product	Acid neutralization plus acid suppression	Compatibility and regulatory positioning
Extended-release product	Longer duration	Higher development and regulatory burden
Low-color or color-free tablet	Clean-label positioning	Appearance and product identification
Sugar-free chewable	Diabetes-conscious positioning	Sweetener taste and texture

The strongest near-term opportunities are chewable tablets, orally disintegrating tablets and portable unit-dose formats. These products address use occasions where standard tablets are less convenient. A new product must manage the bitter taste of famotidine through sweeteners, flavors, polymeric taste masks, coated particles or granulation techniques.

How can excipients support commercial differentiation?

Excipients can create differentiation in four areas.

Faster perceived onset

Disintegration and wetting can influence consumer perception of onset. A formulation with rapid disintegration can support "fast dissolve" or similar positioning, subject to substantiation and labeling rules. The formulation should not imply a pharmacologic effect that the clinical data do not support.

Better swallowability

A smaller tablet, smoother coating and lower tablet friability can improve adherence and repeat purchase. This is relevant for frequent heartburn users and older consumers.

Better portability

Blister packaging, stick packs and individually wrapped chewables can expand use during travel, work and dining occasions. Packaging can be a stronger commercial differentiator than the excipient system itself.

Ingredient-positioning claims

Sugar-free, dye-free, gluten-free or lactose-free positioning may improve appeal in selected channels. Each claim requires supplier documentation, finished-product controls and market-specific review. Excipient changes should not be made solely for marketing value if they increase dissolution variability or stability risk.

What manufacturing and IP barriers affect Zantac 360 competitors?

Manufacturing barriers are moderate rather than high. Standard immediate-release famotidine tablets can be produced by direct compression or wet granulation, depending on powder flow, dose uniformity and tablet strength.

The main barriers are:

• Consistent low-dose content uniformity.
• Control of blend segregation.
• Reliable disintegration after coating.
• Supplier qualification and excipient variability.
• Long-term stability under retail conditions.
• Packaging-line speed and tablet inspection.
• Taste masking for chewable or orally disintegrating products.
• Control of nitrite, peroxide and unknown impurities.
• Reliable famotidine API supply.
• Compliance with OTC labeling and quality-system requirements.

Manufacturing know-how may create cost advantages, but it is difficult to use as a market exclusion tool unless protected by enforceable process claims or confidentiality obligations.

What generic entry risks exist for Zantac 360?

Generic entry risk is high for the conventional tablet category. Famotidine is widely available from generic manufacturers, contract development and manufacturing organizations, wholesalers and retail private-label suppliers.

The risk profile differs by product type:

Competitor type	Entry risk to Zantac 360	Primary competitive lever
Generic 10 mg tablet	High	Price
Generic 20 mg tablet	High	Price and availability
Store-brand famotidine	High	Retailer margin
Pepcid	High	Established brand
Chewable famotidine	Moderate	Convenience and taste
Orally disintegrating famotidine	Moderate	Delivery format
Famotidine-antacid combination	Moderate	Multi-mechanism positioning
Liquid famotidine	Moderate	Pediatric and specialty use
Proton-pump inhibitor	Indirect	Longer acid suppression
Alginate or antacid product	High indirect pressure	Rapid symptom relief

The most exposed revenue is associated with standard tablet sales in price-sensitive retail channels. Premium pricing is more defensible in differentiated formats, multipacks, travel packs and products with strong consumer-preference attributes.

What patent litigation and settlement risks affect Zantac 360?

No broad molecule-level patent dispute is expected to protect Zantac 360 from generic famotidine entry. Litigation risk would arise if a sponsor asserts patents covering:

• A specific chewable or orally disintegrating formulation.
• A taste-masking technology.
• A dissolution profile.
• A combination product.
• A packaging configuration.
• A manufacturing process.
• A method of treating a particular heartburn population.

Settlement agreements are less likely to create meaningful market-wide protection for standard famotidine tablets because multiple noninfringing formulations are available. A settlement could still affect a specific product or dosage form if a competitor’s application relies on a listed formulation patent.

Trademark enforcement is more important for Zantac 360 than molecule-level patent enforcement. Competitors must avoid confusingly similar use of "Zantac," the Zantac 360 product name, logos and trade dress.

How does Zantac 360 compare with Pepcid and generic famotidine?

Factor	Zantac 360	Pepcid	Generic famotidine
Active ingredient	Famotidine	Famotidine	Famotidine
Brand strength	Repositioned legacy brand	Established H2-blocker brand	Low to moderate
Price position	Premium or mid-premium	Premium	Low
Formulation differentiation	Conventional tablet platform with extension potential	Broad consumer familiarity and product variants	Usually limited
Main protection	Trademark and commercial execution	Trademark and commercial execution	Cost and distribution
Regulatory risk	OTC labeling and quality compliance	OTC labeling and quality compliance	ANDA or applicable OTC pathway
Generic entry exposure	High	High	Not applicable
Consumer trust issue	Requires separation from ranitidine history	Established famotidine association	Variable by manufacturer

Zantac 360 can compete successfully only if the brand communicates that the active ingredient is famotidine and maintains reliable quality. It cannot depend on historical ranitidine franchise protection.

What are the most attractive commercial opportunities?

The highest-value opportunities are:

1. A chewable famotidine tablet with effective bitterness control.
2. A fast-dissolving tablet with a smaller unit size.
3. A sugar-free, low-color or dye-free formulation.
4. A travel-oriented blister or stick-pack presentation.
5. A dual-action product combining famotidine with an antacid, subject to regulatory review.
6. A pediatric or liquid presentation with controlled dosing.
7. A premium product supported by documented impurity and stability controls.
8. Contract manufacturing of private-label famotidine products.
9. Excipient supply packages designed for low-nitrite and low-peroxide performance.
10. Packaging systems that improve moisture protection and dose portability.

The commercial risk is that excipient innovation may increase cost without creating a defensible claim. The preferred strategy is a low-complexity reformulation that improves consumer use, protects dissolution and stability, and creates a differentiated package or dosage form.

Key Takeaways

• Zantac 360 contains famotidine and competes in a mature OTC H2-blocker market.
• The active ingredient provides little current exclusivity.
• Trademark, retail distribution, formulation execution and consumer trust are more important than core patent protection.
• Standard famotidine tablets face high generic and private-label entry risk.
• Excipient priorities include rapid disintegration, taste masking, coating control, supply continuity and impurity management.
• Chewable, orally disintegrating, liquid and portable unit-dose products offer the strongest formulation opportunities.
• Nitrite, peroxide, moisture and supplier variability should be controlled because of the broader acid-reducer quality history.
• Biosimilar risk is irrelevant; the commercial threat is generic and branded OTC substitution.
• A formulation patent may protect a specific dosage form but is unlikely to block the broader famotidine market.
• Packaging and brand execution may produce more durable commercial value than incremental excipient changes.

FAQs

Is famotidine in Zantac 360 the same as famotidine in generic Pepcid?

Yes. Both products use famotidine as the active ingredient, although inactive ingredients, dosage forms, strengths, labeling and manufacturing controls can differ.

Can a company patent a new Zantac 360 excipient formulation?

A company may seek patent protection for a novel and nonobvious excipient system, taste-masking method, dissolution profile, combination product or manufacturing process. A conventional substitution of one common tablet excipient for another is less likely to support strong patent protection.

Does Zantac 360 contain ranitidine?

No. Zantac 360 uses famotidine rather than ranitidine.

Are excipient changes to an OTC famotidine tablet commercially significant?

Yes. Changes can affect dissolution, stability, taste, tablet size, consumer acceptance, manufacturing cost and retailer positioning. They may also require regulatory documentation or a supplement, depending on the product and the change.

Can private-label retailers launch a competing famotidine product?

Yes. Private-label products can enter through an applicable FDA-approved or OTC regulatory pathway, provided the sponsor meets requirements for active ingredient, manufacturing, labeling, quality and packaging.

References

1. U.S. Food and Drug Administration. (2020). FDA requests removal of all ranitidine products from the market. https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-market

2. DailyMed. (n.d.). Zantac 360 famotidine tablet: Product labeling and inactive ingredients. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2023). Control of nitrosamine impurities in human drugs. https://www.fda.gov/drugs/drug-safety-and-availability

4. U.S. Food and Drug Administration. (1995). Pepcid AC OTC approval and famotidine labeling history. FDA Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (2014). SUPAC-IR: Immediate-release solid oral dosage forms: Scale-up and postapproval changes. https://www.fda.gov/regulatory-information

6. United States Pharmacopeia. (2024). USP-NF general chapters and excipient quality standards. United States Pharmacopeial Convention. https://www.usp.org/standards/compendial-standards/usp-nf